Note: Ingredients listed on restricted chemical lists
EC/CAS
219-854-2/2551-62-4
Name of the chemical
Sulfur hexafluoride
Concentration
N/A
EC/CAS
200-312-9/57-10-3
Name of the chemical
palmitic acid
Concentration
N/A
General Information
Revision date
2016-12-01
Product name
SonoVue (25 mg under sulfur hexafluoride gas) / LUMASON
Product Synonyms
Sulfur hexafluoride microbubbles for injection
Chemical name
For active, sulfur hexafluoride
CAS No.
2551-62-4
Emergency telephone
1-800-257-5181, 1-800-424-9300, 1-703-527-3887
Icons in SDS
Company Information
company name
Bracco Diagnostics Inc
e-mail address of the competent person responsible for the Safety Data Sheet
services@reachteam.eu
GHS Information
Signal word
Not applicable
Section 2
SECTION 2: Hazards identification
NFPA Rating Classification of the substance or mixture The product is not classified according to the Globally Harmonized System (GHS)
2.2 Label elements
Not applicable
Hazard pictograms
Not applicable
Signal word
Not applicable
Hazard statements
Not applicable Effects of Overexposure - Routes of Entry: Inhalation: Under normal conditions, this material is handled in closed vials and exposure by inhalation is not expected to occur. Sulfur hexafluoride is a gas that is absorbed following inhalation but rapidly exhaled. Skin Contact: Exposure may occur via skin contact if gloves and protective clothing are not worn. No information for absorption through skin. Ingestion: Ingestion of large quantities of this material in an occupational setting would not be expected to occur. Ingestion of trace amounts of the material might occur if the material contacts hands and hands are not washed prior to eating, drinking or smoking. The extent of systemic absorption of the powder and gas after ingestion is not known. Note: When prepared in a clinical setting, physiological saline for injection is added to the vial containing sulfur hexafluoride and lyophile. The resulting solution is intended for intravenous injection, under the care of a physician.
Additional information
Information pertaining to particular dangers for man and environment: Negative Effects on the Health: See also Sections 11 Negative Effects on the Environment: See also Section 12 NFPA ratings (scale 0 - 4) Health=0 0 Fire=0 0 Reactivity=0 HMIS-ratings (scale 0 - 4) HEALTH 0 Health=0 FIRE 0 Fire=0 REACTIVITY 0 Reactivity=0
PBT Substances
Not applicable
vPvB Substances
Not applicable Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 41
2.1 Classification of the substance or mixture
The product is not classified according to the Globally Harmonized System (GHS). Label elements GHS label elements Not applicable. Hazard pictograms Not applicable. Signal word Not applicable. Hazard statements Not applicable. Effects of Overexposure - Routes of Entry: Inhalation: Under normal conditions, this material is handled in closed vials and exposure by inhalation is not expected to occur. Sulfur hexafluoride is a gas that is absorbed following inhalation but rapidly exhaled. Skin Contact: Exposure may occur via skin contact if gloves and protective clothing are not worn. No information for absorption through skin. Ingestion: Ingestion of large quantities of this material in an occupational setting would not be expected to occur. Ingestion of trace amounts of the material might occur if the material contacts hands and hands are not washed prior to eating, drinking or smoking. The extent of systemic absorption of the powder and gas after ingestion is not known. Note: When prepared in a clinical setting, physiological saline for injection is added to the vial containing sulfur hexafluoride and lyophile. The resulting solution is intended for intravenous injection, under the care of a physician. Additional Information: Information pertaining to particular dangers for man and environment: Negative Effects on the Health: See also Sections 11 Negative Effects on the Environment: See also Section 12 NFPA ratings (scale 0 - 4) Health=0 0 Fire=0 0 Reactivity=0 HMIS-ratings (scale 0 - 4) HEALTH 0 Health=0 FIRE 0 Fire=0 REACTIVITY 0 Reactivity=0 Results of PBT and vPvB assessment PBT: Not applicable. vPvB: Not applicable. Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 41 3 COMPOSITION/INFORMATION ON INGREDIENTS Chemical characterization: Substances Active Ingredient: CAS: 2551-62-4 sulphur hexafluoride Press. Gas, H280 EINECS: 219-854-2 Impurities and stabilising additives: CAS: 67232-81-9 Sodium Dipalmitoylphosphatidylglycerol (DPPG) CAS: 816-94-4 Diasteroylphosphatidylcholine (DSPC) CAS: 57-10-3 EINECS: 200-312-9 palmitic acid, pure RTECS: RT 4550000 Chemical characterization: Mixtures Description: Mixture: consisting of the following components. Hazardous Components: CAS: 2551-62-4 sulphur hexafluoride Press. Gas, H280 EINECS: 219-854-2 > 1% INDICATIONS AND USAGE1 LUMASON is an ultrasound contrast agent indicated for use: • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients CONTRAINDICATIONS1 LUMASON is contraindicated in patients with: • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON IMPORTANT SAFETY INFORMATION1 WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)]. • Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)]. • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)]. T The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].1 Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike). LUMASON is a registered trademark of Bracco Diagnostics Inc. SonoVue is a registered trademark of Bracco Suisse S.A. 1. LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; December 2016. Bracco Diagnostics Inc. 259 Prospect Plains Road, Building H, Monroe Township, NJ 08831 USA Phone: 609-514-2200 Toll Free: 1-877-272-2269 (U.S. only) Fax: 609-514-2446 ©2018 Bracco Diagnostics Inc. All Rights Reserved. 42 4 FIRST-AID MEASURES Description of first aid measures General information: No special measures required. After Inhalation: Supply fresh air. If required, provide artificial respiration. After Skin Contact: Remove contaminated clothing. Wash with water and rinse thoroughly for 5 minutes. Seek medical attention if irritation (redness, itching or swelling) develops or persists. After Eye Contact: Wash with running water for several minutes holding the eyelids open. If any symptoms of irritation develop and / or persist, consult your doctor. After Swallowing: Get medical attention immediately. Vomiting may be induced only if a person is conscious and if ingestion has occurred within the past three hours. Never induce vomiting in a person who is unconscious or experiencing convulsions. Most important symptoms and effects, both acute and delayed See also Section 2 and 11. Indication of any immediate medical attention and special treatment needed No further relevant information available. Means of Specific and Immediate Treatment to Keep at the Workplace: No special measures required. Note to physicians: None. 5 FIRE-FIGHTING MEASURES Extinguishing media Suitable extinguishing agents: In case of fire, flood with Water For safety reasons unsuitable extinguishing agents: Unknown. Special hazards arising from the substance or mixture See also Section 10. Hazardous Combustion Products: Carbon Dioxide (CO2) In the absence of Oxygen: Carbon Monoxide (CO) Hydrogen Fluoride (HF) Sulfur Oxides (SOx) Additional Information: Not Available Advice for Firefighters Evacuate personnel to an upwind direction, remove unneeded material and cool container(s) with water from a maximum distance. Move container from fire area if you can do it without risk. Protective Equipment: Firefighters should wear adequate personal protective equipment with protection of respiratory tract (selfcontained breathing apparatus) (SCBA). Wear flame and chemicals resistant clothing, boots and gloves (see Section 8). Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 43 6 ACCIDENTAL RELEASE MEASURES Personal precautions, protective equipment and emergency procedures Avoid inhalation of dust / fog. ²Wear protective equipment appropriate to the circumstances (see Section 8) Environmental precautions: Do not allow product to reach sewage system or any water course. Methods and material for containment and cleaning up: Sweep material onto paper and place into a fiber drum for reclamation or disposal. The spill area should be ventilated and decontaminated after material has been picked up. Reference to other sections See Section 7 for information on Safe Handling. See Section 8 for information on Personal Protection Equipment. See Section 13 for Disposal Information. See Section 12 for Ecological Information. INDICATIONS AND USAGE1 LUMASON is an ultrasound contrast agent indicated for use: • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients CONTRAINDICATIONS1 LUMASON is contraindicated in patients with: • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON IMPORTANT SAFETY INFORMATION1 WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)]. • Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)]. • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)]. T The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].1 Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike). LUMASON is a registered trademark of Bracco Diagnostics Inc. SonoVue is a registered trademark of Bracco Suisse S.A. 1. LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; December 2016. Bracco Diagnostics Inc. 259 Prospect Plains Road, Building H, Monroe Township, NJ 08831 USA Phone: 609-514-2200 Toll Free: 1-877-272-2269 (U.S. only) Fax: 609-514-2446 ©2018 Bracco Diagnostics Inc. All Rights Reserved. 44 7 HANDLING AND STORAGE Precautions for Safe Handling Avoid skin and eye contact. Conditions for Safe Storage, including any Incompatibilities Requirements to be met by Storerooms and Receptacles: Store in a cool, dry place in tightly closed receptacles. Container Requirements: Kit consists of a clear glass vial, transfer system and a 5 mL of sterile physiological saline. Five kits are provided per carton. Storage Conditions: Store at 15-30 degrees C (59 to 86 degrees F). Information about Storage in one Common Storage Facility: Not required. Further information about storage conditions: None. Specific end use(s) No further relevant information available. 8 EXPOSURE CONTROLS/PERSONAL PROTECTION Additional information about design of technical systems: No further data; see item 7. Control parameters Components with limit values that require monitoring at the workplace: 2551-62-4 sulphur hexafluoride PEL (USA) 6000 mg/m³, 1000 ppm REL (USA) 6000 mg/m³, 1000 ppm TLV (USA) 5970 mg/m³, 1000 ppm 25322-68-3 Polyethylene glycol 4000 OSHA-PEL (USA) 15 mg/m³ 10 mg/m³ TLV-TWA (USA) 10 mg/m³ WEEL (USA) Form: Aerosol Additional information: The lists that were valid during the creation were used as basis. Exposure controls Appropriate Technical Controls: Provide adequate aspiration / ventilation in the workplace Additional information about Design of Technical Facilities: No further data (see Section 7). Personal protective equipment General Protective and Hygienic Measures: The usual precautionary measures for handling chemicals should be followed. Wash hands before breaks and at the end of work. Wear protective equipment (PPE) appropriate to the circumstances. Do not eat, drink, smoke while working. Provide appropriate ventilation. Breathing Equipment: Not anticipated for normal clinical environment. In non-routine exposure conditions, where risk assessment shows air-purifying respirators are appropriate, use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Self-contained breathing apparatus should be available for emergency use. Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 45 8 EXPOSURE CONTROLS/PERSONAL PROTECTION (continued) Protection of Hands: Wear impervious gloves if the potential exists for dermal contact. Material of Gloves: Latex, Latex / Nitrile or Nitrile Gloves. The selection of the suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer. Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation. The glove material has to be impermeable and resistant to the product/ the substance/ the mixture. Penetration Time of Glove Material: The exact break through time has to be found out by the manufacturer of the protective gloves and has to be observed. Eye Protection: Tightly sealed goggles Body Protection: In the case of high concentrations of dust, we recommend using lightweight disposable protective clothing Limitation and Supervision of Exposure into the Environment: See also Section 7. Additional Information about Design of Technical Systems: No further data; see Section 7. INDICATIONS AND USAGE1 LUMASON is an ultrasound contrast agent indicated for use: • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients CONTRAINDICATIONS1 LUMASON is contraindicated in patients with: • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON IMPORTANT SAFETY INFORMATION1 WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)]. • Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)]. • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)]. T The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].1 Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike). LUMASON is a registered trademark of Bracco Diagnostics Inc. SonoVue is a registered trademark of Bracco Suisse S.A. 1. LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; December 2016. Bracco Diagnostics Inc. 259 Prospect Plains Road, Building H, Monroe Township, NJ 08831 USA Phone: 609-514-2200 Toll Free: 1-877-272-2269 (U.S. only) Fax: 609-514-2446 ©2018 Bracco Diagnostics Inc. All Rights Reserved. 46 9 PHYSICAL AND CHEMICAL PROPERTIES Information on basic physical and chemical Chemical Properties For polyethylene glycol 4000 (PEG 4000) unless indicated properties otherwise. General Information Appearance: Form: Powder Color: White Odor: PEG 4000: Mild Odor SF6: Odorless Odour threshold: Not determined. pH-value: 4.5 - 7.5 ( of solution ) Flash point: PEG 4000: Fp = 246 °C (Closed Cup) SF6: Fp = Not Flammable. Flammability (solid, gaseous): Not determined. Ignition temperature: Decomposition temperature: Not determined. Auto igniting: Product is not selfigniting. Danger of explosion: Product does not present an explosion hazard. Density at 20 °C: 1.108 g/cm³ Relative density Not determined. Vapour density 5.1 ( SF6; Air = 1.0 ) Solubility in / Miscibility with Water: PEG 4000: Soluble in Water SF6: Slightly Soluble in Water Partition coefficient (n-octanol/water): Not determined. Viscosity: Dynamic: Not applicable. Kinematic: Not applicable. Other information No further relevant information available. Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 47 10 STABILITY AND REACTIVITY Reactivity: There are not particular dangerous reactions with other substances in normal conditions of use. Chemical stability: Stable under normal conditions. Possibility of hazardous reactions: No dangerous reactions known. Conditions to avoid: No further relevant information available. Incompatible materials: No further relevant information available. Hazardous decomposition products: No further relevant information available (See Section 5) INDICATIONS AND USAGE1 LUMASON is an ultrasound contrast agent indicated for use: • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients CONTRAINDICATIONS1 LUMASON is contraindicated in patients with: • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON IMPORTANT SAFETY INFORMATION1 WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)]. • Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)]. • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)]. T The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].1 Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike). LUMASON is a registered trademark of Bracco Diagnostics Inc. SonoVue is a registered trademark of Bracco Suisse S.A. 1. LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; December 2016. Bracco Diagnostics Inc. 259 Prospect Plains Road, Building H, Monroe Township, NJ 08831 USA Phone: 609-514-2200 Toll Free: 1-877-272-2269 (U.S. only) Fax: 609-514-2446 ©2018 Bracco Diagnostics Inc. All Rights Reserved. 48 11 TOXICOLOGICAL INFORMATION Information on toxicological effects Acute toxicity: Toxicological Information for Active Ingredients: LD/LC50 values that are relevant for classification: 2551-62-4 sulphur hexafluoride LD50 ivn 5790 mg/kg (Rabbit) Primary irritant effect: By Inhalation: Inhaling small amounts of sulfur hexafluoride or airborne dust from the powder would not be expected to produce symptoms. By Ingestion: Inadvertent ingestion of trace amounts of this material would not be expected to result in symptoms. On the skin: Material contains low concentration of components that are mild irritants or possible irritants. It may have potential to cause mild irritation, however , moderate or severe irritation is not expected. On the eyes: May cause irritation. Significant exposure to cold sulfur hexafluoride gas can cause frostbite of the eye. CMR effects (carcinogenicity, mutagenicity and toxicity for reproduction): Sensitization: This material may act as a sensitizer (allergen) for those persons who are allergic to the formulation or components in the formulation. Germ Cell Mutagenicity: A number of in vitro and in vivo mutagenicity studies did not show mutagenicity for SonoVue. Carcinogenicity: Not Available. Reproductive Toxicity: Reproduction studies with SonoVue in rats and rabbits at daily doses up to 17 times and 35 times the normal dose, respectively, did not show impaired fertility or harm to the fetus. Specific Target Organ Toxicity Single Exposure (STOT - SE): No further relevant information available Repeated Exposure (STOT - RE): No further relevant information available Aspiration Hazard: No further relevant information available Other information (about experimental toxicology): SonoVue did not cause acute toxicity in monkeys when administered intravenously at a dose at least 139 times the human exposure based upon body surface area. Subacute to Chronic Toxicity: No harmful effects are expected from SonoVue under normal use conditions. Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 49 11 TOXICOLOGICAL INFORMATION (continued) Carcinogenic Categories IARC (International Agency for Research on Cancer) None of the ingredients is listed. NTP (National Toxicology Program) None of the ingredients is listed. OSHA-Ca (Occupational Safety & Health Administration) None of the ingredients is listed. Additional toxicological information: Contact with small quantities of material for short periods is not expected to result in pharmacologic or toxic effects. The safety of SonoVue in patients with cardiac shunts has not been studied. Extreme caution should be exercised when considering administration of SonoVue to patients with congenital heart defects. Significant exposure to cold sulfur hexafluoride gas can cause frostbite. Any Eventual Delayed Effect after Prolonged Exposure: Repeated and prolonged exposure to skin may cause skin irritation. INDICATIONS AND USAGE1 LUMASON is an ultrasound contrast agent indicated for use: • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients CONTRAINDICATIONS1 LUMASON is contraindicated in patients with: • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON IMPORTANT SAFETY INFORMATION1 WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)]. • Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)]. • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)]. T The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].1 Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike). LUMASON is a registered trademark of Bracco Diagnostics Inc. SonoVue is a registered trademark of Bracco Suisse S.A. 1. LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; December 2016. Bracco Diagnostics Inc. 259 Prospect Plains Road, Building H, Monroe Township, NJ 08831 USA Phone: 609-514-2200 Toll Free: 1-877-272-2269 (U.S. only) Fax: 609-514-2446 ©2018 Bracco Diagnostics Inc. All Rights Reserved. 50 12 ECOLOGICAL INFORMATION Toxicity Aquatic toxicity: No further relevant information available. Persistence and degradability No further relevant information available. Bioaccumulative potential No further relevant information available. Mobility in soil: No further relevant information available. General notes: Generally not hazardous for water. Avoid transfer into the environment. Results of PBT and vPvB assessment PBT: Not applicable. vPvB: Not applicable. Other adverse effects No further relevant information available. Additional Information: Use according to good working practice. 13 DISPOSAL CONSIDERATIONS Waste treatment methods: Recommendation: Must not be disposed of together with household garbage. Do not allow product to reach sewage system. Reutilise if possible or contact a waste processors for recycling or safe disposal. Uncleaned packagings: Recommendation: Dispose in accordance with national, state, local or applicable country regulations. Recommended cleansing agent: Water, if necessary with cleansing agents. Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 51 14 TRANSPORT INFORMATION UN-Number Void DOT, ADR, ADN, IMDG, IATA UN proper shipping name DOT, ADR, ADN, IMDG, IATA Void Transport hazard class(es) ADR, ADN, IMDG, IATA Void Class Packing group Void DOT, ADR, IMDG, IATA Environmental hazards: Marine pollutant: No Special precautions for user Not applicable. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code Not applicable. UN “Model Regulation”: - INDICATIONS AND USAGE1 LUMASON is an ultrasound contrast agent indicated for use: • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients CONTRAINDICATIONS1 LUMASON is contraindicated in patients with: • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON IMPORTANT SAFETY INFORMATION1 WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)]. • Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)]. • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)]. T The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].1 Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike). LUMASON is a registered trademark of Bracco Diagnostics Inc. SonoVue is a registered trademark of Bracco Suisse S.A. 1. LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; December 2016. Bracco Diagnostics Inc. 259 Prospect Plains Road, Building H, Monroe Township, NJ 08831 USA Phone: 609-514-2200 Toll Free: 1-877-272-2269 (U.S. only) Fax: 609-514-2446 ©2018 Bracco Diagnostics Inc. All Rights Reserved. 52 15 REGULATORY INFORMATION Safety, health and environmental regulations/legislation specific for the substance or mixture Sara Section 355 (extremely hazardous substances): None of the ingredients is listed. Section 313 (Specific toxic chemical listings): None of the ingredients is listed. TSCA (Toxic Substances Control Act): 2551-62-4 sulphur hexafluoride 25322-68-3 Polyethylene glycol 4000 57-10-3 palmitic acid, pure Proposition 65 Chemicals known to cause cancer: None of the ingredients is listed. Chemicals known to cause reproductive toxicity for females: None of the ingredients is listed. Chemicals known to cause reproductive toxicity for males: None of the ingredients is listed. Chemicals known to cause developmental toxicity: None of the ingredients is listed. Carcinogenic categories EPA (Environmental Protection Agency) None of the ingredients is listed. TLV (Threshold Limit Value established by ACGIH) None of the ingredients is listed. NIOSH-Ca (National Institute for Occupational Safety and Health) None of the ingredients is listed. GHS label elements Not applicable. Hazard pictograms Not applicable. Signal word Not applicable. Hazard statements Not applicable. Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 53 16 OTHER INFORMATION This information is based on our present knowledge. However, this shall not constitute a guarantee for any specific product features and shall not establish a legally valid contractual relationship. Significant Dangers: Relevant phrases H280 Contains gas under pressure; may explode if heated. Training Hints: All persons handling this product should be informed on the existence of the hazard, on any possible risk they might be subjected to and about all required protective measures to prevent such a damage or to reduce the exposition. WARNINGS: Diagnostic agents are intended for use under direction of a physician and/or under the conditions of use described on the label and in the product’s package insert. As a general precaution, personnel who handle drug substances should avoid contact (ingestion, inhalation, skin and eye contact) with these substances. Department issuing SDS: B-Lands Consulting WTC, 5 Place Robert Schuman, BP 1516 38025 Grenoble, FRANCE Tel: +33 476 295 869 Fax: +33 476 295 870 services@reachteam.eu www.reachteam.eu Date of preparation / last revision 11/07/2014 / - Abbreviations and acronyms: RID: Règlement international concernant le transport des marchandises dangereuses par chemin de fer (Regulations Concerning the International Transport of Dangerous Goods by Rail) ICAO: International Civil Aviation Organisation ADR: Accord européen sur le transport des marchandises dangereuses par Route (European Agreement concerning the International Carriage of Dangerous Goods by Road) IMDG: International Maritime Code for Dangerous Goods IATA: International Air Transport Association ACGIH: American Conference of Governmental Industrial Hygienists EINECS: European Inventory of Existing Commercial Chemical Substances ELINCS: European List of Notified Chemical Substances CAS: Chemical Abstracts Service (division of the American Chemical Society) NFPA: National Fire Protection Association (USA) HMIS: Hazardous Materials Identification System (USA) LC50: Lethal concentration, 50 percent LD50: Lethal dose, 50 percent Press. Gas: Gases under pressure: Liquefied gas * Data compared to the previous version altered. - data updating on the basis of the latest amendments. - adaptation of the form according to Regulation 1907/2006/CE. Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 54 Ultrasound From Bracco Diagnostics Inc.— A GLOBAL LEADER IN ENHANCED ULTRASOUND FDA APPROVAL LETTERS Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 55 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 203684 NDA APPROVAL Bracco Diagnostics Inc. Attention: Melanie Benson Director, U.S. Regulatory Operations 259 Prospect Plains Road, Bldg. H Monroe Township, NJ 08831 Dear Ms. Benson: Please refer to your New Drug Application (NDA) dated December 21, 2011, received December 21, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lumason (sulfur hexafluoride lipid-type A microspheres) for injectable suspension. We acknowledge receipt of your amendments dated January 27, February 9 and 27, March 2, April 19 and 26, May 10, June 19, July 23, September 13, December 7 and 14, 2012; January 7, May 31 (2), August 19, September 13 and 25, November 12, 2013; April 11, May 9, June 9, June 18, September 5 and 29, 2014. The April 11, 2014, submission constituted a complete response to our November 27, 2013, action letter. This new drug application provides for the use of Lumason (sulfur hexafluoride lipid-type-A microspheres) for injectable suspension for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text. CONTENT OF LABELING As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for 56 Reference ID: 3641921 NDA 203684 Content of Labeling Technical Qs and As, available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U CM072392.pdf. The SPL will be accessible via publicly available labeling repositories. CARTON AND IMMEDIATE CONTAINER LABELS Submit final printed carton and immediate container labels that are identical to the enclosed carton and immediate container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008). Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “Final Printed Carton and Container Labels for approved NDA 203684.” Approval of this submission by FDA is not required before the labeling is used. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug. MARKET PACKAGE Please submit one market package of the drug product when it is available to the following address: Frank Lutterodt Food and Drug Administration Center for Drug Evaluation and Research White Oak Building 5483, Room: 5483 10903 New Hampshire Avenue Silver Spring, Maryland Use zip code 20903 if shipping via United States Postal Service (USPS). Use zip code 20993 if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx). ADVISORY COMMITTEE Your application for Lumason (sulfur hexafluoride lipid-type A microspheres) for injectable suspension was not referred to an FDA advisory committee because the application did not raise significant public health questions on the role of the drug in the diagnosis, cure, mitigation, treatment, or prevention of a disease. Furthermore, outside expertise was not necessary; there were no controversial issues that would benefit from advisory committee discussion. 57 Reference ID: 3641921 NDA 203684 REQUIRED PEDIATRIC ASSESSMENTS Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable. We are waiving the pediatric study requirement for ages birth to less than 9 years because necessary studies are impossible or highly impracticable. This is because the number of pediatric patients younger than 9 years of age with poor non-contrast echocardiography is small. We are deferring submission of your pediatric study for ages 9 to 17 years for this application because this product is ready for approval for use in adults and the pediatric study has not been completed. Your deferred pediatric study required by section 505B(a) of the FDCA is a required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(3)(B) of the FDCA. This required study is listed below. 2803-1 Deferred pediatric study under PREA: Conduct a multicenter clinical evaluation of safety and efficacy in pediatric patients ages 9-17 years of age of Lumason as a contrast agent in pediatric echocardiography. Evaluate the efficacy of Lumason contrasted echocardiography vs. non-contrast echocardiography for left ventricular border delineation in 92 patients (males and females) 9-17 years old. During the clinical evaluation, pharmacokinetic assessments will be performed on 6 patients, 9-12 years old (3 males and 3 females) and 6 patients 12-17 years old (3 males and 3 females). Draft Protocol Submitted: February 25, 2014 Final Protocol Submission: October 31, 2014 Study Completion (Including Blinded Read): December 31, 2017 Final Report Submission: May 31, 2018 Submit the protocol(s) to your IND 046958, with a cross-reference letter to this NDA. Reports of this required pediatric postmarketing study must be submitted as a new drug application (NDA) or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from these studies. When submitting the reports, please clearly mark your submission "SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS" in large font, bolded type at the beginning of the cover letter of the submission. 58 Reference ID: 3641921 NDA 203684 PROMOTIONAL MATERIALS You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to: Food and Drug Administration Center for Drug Evaluation and Research Office of Prescription Drug Promotion 5901-B Ammendale Road Beltsville, MD 20705-1266 As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm. REPORTING REQUIREMENTS We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81). MEDWATCH-TO-MANUFACTURER PROGRAM The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm. POST APPROVAL FEEDBACK MEETING New molecular entities and new biologics qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, call the Regulatory Project Manager for this application. 59 Reference ID: 3641921 NDA 203684 If you have any questions, call Frank Lutterodt, Regulatory Project Manager, at (301) 796-4251. Sincerely, {See appended electronic signature page} Charles Ganley, M.D. Director Office of Drug Evaluation IV Center for Drug Evaluation and Research Enclosures: Content of Labeling Carton and Container Labeling 60 Reference ID: 3641921 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- CHARLES J GANLEY 10/10/2014 Reference ID: 3641921 61 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 203684/S-001 SUPPLEMENT APPROVAL Bracco Diagnostics Inc. Attention: Melanie Benson Director, US Regulatory Operations 259 Prospect Plains Road, Building H Monroe Township, NJ 08831 Dear Ms. Benson: Please refer to your Supplemental New Drug Application (sNDA) dated June 4, 2015, received June 4, 2015, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lumason; (Sulfur Hexafluoride Lipid-Type A Microspheres) for Injectable Suspension. We acknowledge receipt of your amendments dated June 22, July 10, October 21, 23, and 29, November 6, 18, and 24, December 17, and 18, 2015; and February 22, March 3 (2), 4, 16, 17, 21, 28, 30, and 31, 2016. This new drug application provides for the use of Lumason; (Sulfur Hexafluoride Lipid-Type A Microspheres) for Injectable Suspension for use in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients. APPROVAL & LABELING We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text. CONTENT OF LABELING As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert,) with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. 62 Reference ID: 3910678 NDA 203684/S-001 Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/U CM072392.pdf The SPL will be accessible from publicly available labeling repositories. Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked- up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s). CARTON AND IMMEDIATE CONTAINER LABELS We acknowledge your June 4, 2015, submission containing final printed carton and container labels. MARKET PACKAGE Please submit one market package of the drug product when it is available to the following address: Modupe Fagbami Food and Drug Administration Center for Drug Evaluation and Research White Oak Building 22, Room: 5439 10903 New Hampshire Avenue Silver Spring, Maryland Use zip code 20903 if shipping via United States Postal Service (USPS). Use zip code 20993 if sending via any carrier other than USPS (e.g., UPS, DHL, FedEx). REQUIRED PEDIATRIC ASSESSMENTS Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable. We note that you have fulfilled the pediatric study requirements for all relevant pediatric age groups for this application. 63 Reference ID: 3910678 NDA 203684/S-001 PROMOTIONAL MATERIALS You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to: OPDP Regulatory Project Manager Food and Drug Administration Center for Drug Evaluation and Research Office of Prescription Drug Promotion (OPDP) 5901-B Ammendale Road Beltsville, MD 20705-1266 Alternatively, you may submit a request for advisory comments electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U CM443702.pdf ). You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm. All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above, by fax to 301-847-8444, or electronically in eCTD format. For more information about submitting promotional materials in eCTD format, see the draft Guidance for Industry (available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/U CM443702.pdf ). REPORTING REQUIREMENTS We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81). 64 Reference ID: 3910678 NDA 203684/S-001 If you have any questions, call Modupe Fagbami, Regulatory Project Manager, at (301) 796-1348. Sincerely, {See appended electronic signature page} Libero Marzella, M.D., Ph.D. Director Division of Medical Imaging Products Office of Drug Evaluation IV Center for Drug Evaluation and Research Enclosures: Content of Labeling Carton and Container Labeling 65 Reference ID: 3910678 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- LIBERO L MARZELLA 03/31/2016 Reference ID: 3910678 66 67 68 69 INDICATIONS AND USAGE1 LUMASON is an ultrasound contrast agent indicated for use: • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients CONTRAINDICATIONS1 LUMASON is contraindicated in patients with: • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON IMPORTANT SAFETY INFORMATION1 WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)]. • Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)]. • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)]. T The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].1 Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike). LUMASON is a registered trademark of Bracco Diagnostics Inc. SonoVue is a registered trademark of Bracco Suisse S.A. Bracco Diagnostics Inc. 259 Prospect Plains Road, Building H, Monroe Township, NJ 08831 USA Phone: 609-514-2200 Toll Free: 1-877-272-2269 (U.S. only) Fax: 609-514-2446 ©2018 Bracco Diagnostics Inc. All Rights Reserved. 70 Ultrasound From Bracco Diagnostics Inc.— A GLOBAL LEADER IN ENHANCED ULTRASOUND PRESCRIBING INFORMATION Please see full Prescribing Information for LUMASON including boxed WARNING in this document and at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information. 71 Lumason® for injectable suspension, for intravenous use or intravesical use HIGHLIGHTS OF PRESCRIBING INFORMATION ter 2 mL as an intravenous injection in adult pa- 6. Shake vigorously for 20 seconds, mixing all the contents in the vial (see These highlights do not include all the information tients (2.2, 2.4) Figure 6). A homogeneous white milky liquid indicates formation of sulfur needed to use LUMASON® safely and effectively. • Ultrasonography of the liver in adults: After re- hexafluoride lipid microspheres. See full prescribing information for LUMASON. constitution, administer 2.4 mL as an intravenous 7. For preparation of doses greater than or equal to 1 mL, invert the system injection (2.2, 2.4) and slowly withdraw the intended volume of suspension into the syringe LUMASON (sulfur hexafluoride lipid-type A mi- • Ultrasonography of the liver in pediatric patients: (see Figure 7). For preparation of doses less than 1 mL, withdraw 2 mL of 6 7 8 crospheres) for injectable suspension, for intra- After reconstitution, administer 0.03 mL per kg as venous use or intravesical use an intravenous injection, up to a maximum of volume of Lumason to inject by using the 0.2 mL graduations between the 1 mL and 2 mL marks. Initial U.S. Approval: 2014 2.4 mL per injection (2.2, 2.4) 8. Unscrew the syringe from the Mini-Spike (see Figure 8). Peel and remove the diluent label to display the • May repeat dose one time during a single exam- WARNING: SERIOUS CARDIOPULMONARY reconstituted product label. For intravenous administration, immediately connect the syringe to a dose ination (2.2, 2.4) REACTIONS administration line (20 G) and administer as directed under the Administration Instructions below. For intra- • Follow each injection with an intravenous flush of vesical administration, immediately connect the syringe to a sterile urinary catheter (6 french to 8 french) See full prescribing information for complete 0.9% Sodium Chloride Injection (2.2, 2.4) boxed warning and administer as directed under the Administration Instructions below. For intravesical administration in pediatric patients: • Following reconstitution, Lumason suspension contains 1.5 to 5.6 x108 microspheres/mL with 45 mcg/mL of Serious cardiopulmonary reactions, including • Ultrasonography of the urinary tract: After recon- fatalities, have occurred uncommonly during sulfur hexafluoride. stitution, administer 1 mL via sterile 6-8F urinary or following the injection of ultrasound con- • Use immediately after reconstitution. If the suspension is not used immediately after reconstitution, resuspend catheter. Bladder should be first emptied and the microspheres for a few seconds by hand agitation before the suspension is drawn into the syringe. Re- trast agents, including sulfur hexafluoride lipid then partially filled with saline before injection of microspheres (5.1). Most serious reactions oc- Lumason (2.2, 2.4) constituted suspension within a vial may be used for up to 3 hours from the time of its reconstitution. Maintain cur within 30 minutes of administration (5.1). • After Lumason administration, continue filling the the vial containing the reconstituted suspension at room temperature. 2.4 Administration Instructions • Assess all patients for the presence of any bladder with saline until the patient has the urge condition that precludes administration (4). Inspect visually for particulate matter and discoloration prior to administration, whenever solution and container to micturate or at the first sign of back pressure to permit. The reconstituted suspension is milky-white, and does not contain visible particulate matter. Do not use • Always have resuscitation equipment and the infusion ( 2.4) trained personnel readily available (5.1). the single-patient use vial for more than one patient. ------DOSAGE FORMS AND STRENGTHS------ Intravenous Administration ----------RECENT MAJOR CHANGES---------- • For injectable suspension: 25 mg of lipid-type A Administer Lumason as an intravenous bolus injection. Indications and Usage (1) 12/2016 lyophilized powder with headspace fill of 60.7 mg Intravesical Administration in Pediatric Patients Dosage and Administration (2) 12/2016 sulfur hexafluoride in a single-patient use vial for 1. Insert a sterile 6 french to 8 french urinary catheter into the bladder under sterile conditions; Contraindications (4) 12/2016 reconstitution (3) 2. Empty the bladder of urine, and then fill the bladder with saline (sterile 0.9% sodium chloride solution) to Warnings and Precautions (5.3) 12/2016 -------------CONTRAINDICATIONS------------- approximately one third or half of its predicted total volume. The total bladder volume in children is calculated -----------INDICATIONS AND USAGE----------- • History of hypersensitivity reactions to sulfur as [(age in years + 2) x 30] mL; Lumason is an ultrasound contrast agent indicated hexafluoride lipid microsphere components or to 3. Administer Lumason as an intravesical bolus injection through the urinary catheter; for use any of the inactive ingredients in Lumason (4) 4. Continue filling the bladder with saline until the patient has the urge to micturate or at the first sign of back • in echocardiography to opacify the left ventricular --------WARNINGS AND PRECAUTIONS-------- pressure to the infusion. chamber and to improve the delineation of the left • Cardiopulmonary reactions, including fatalities. 5. Immediately following the first voiding, the bladder may be refilled with normal saline for a second cycle of ventricular endocardial border in adult patients Always have resuscitation equipment and trained voiding and imaging, without the need of a second Lumason administration with suboptimal echocardiograms (1) personnel readily available (5.1) 2.5 Imaging Guidelines • in ultrasonography of the liver for characterization of • Hypersensitivity reactions (5.2) Echocardiography focal liver lesions in adult and pediatric patients (1) -----------ADVERSE REACTIONS---------------- After baseline non-contrast echocardiography is complete, Adjust the mechanical index for the ultrasound de- • in ultrasonography of the urinary tract for the eval- Most common adverse reactions (incidence ≥ 0.5%) vice to 0.8 or lower. Continue ultrasound imaging following Lumason injection. uation of suspected or known vesicoureteral re- are headache and nausea (6.1). Ultrasonography of the Liver flux in pediatric patients (1) After identification of the target focal lesion on non-contrast ultrasound examination, hold transducer still while To report SUSPECTED ADVERSE REACTIONS, switching scanner to low mechanical index (≤ 0.4) contrast-specific imaging. Continue ultrasound imaging fol- -------DOSAGE AND ADMINISTRATION------- contact Bracco Diagnostics Inc at 1-800-257-5181 lowing Lumason injection. Avoid intra-arterial injection (2.1, 5.3) or FDA at 1-800-FDA-1088 or www.fda.gov/med- Ultrasonography of the Urinary Tract See Full Prescribing Information for reconstitution watch instructions (2.3) After baseline non-contrast ultrasound examination of the kidney and bladder, switch the scanner to low me- For intravenous injection: See 17 for PATIENT COUNSELING INFORMATION chanical index (≤0.4) contrast specific imaging. Perform continuous alternate ultrasound imaging of the bladder, • Echocardiography: After reconstitution, adminis- December 2016 ureters, and kidneys during filling and voiding of the bladder. FULL PRESCRIBING INFORMATION: CONTENTS* 8 USE IN SPECIFIC POPULATIONS 3 DOSAGE FORMS AND STRENGTHS WARNING: SERIOUS CARDIOPULMONARY RE- 8.1 Pregnancy For injectable suspension: Lumason is supplied as a 3-part single-patient use kit comprised of: ACTIONS 8.2 Lactation • one Lumason clear vial containing 25 mg of lipid-type A sterile white lyophilized powder with headspace filled 8.4 Pediatric Use with 60.7 mg of sulfur hexafluoride gas 1 INDICATIONS AND USAGE 8.5 Geriatric Use • one prefilled syringe containing 5 mL Sodium Chloride 0.9% Injection, USP (Diluent) 2 DOSAGE AND ADMINISTRATION 11 DESCRIPTION • one Mini-Spike 2.1 Important Administration Instructions 12 CLINICAL PHARMACOLOGY Following reconstitution, Lumason is a homogeneous, milky white suspension containing1.5 to 5.6 x108 micro- 2.2 Recommended Dosage 12.1 Mechanism of Action spheres/mL with 45 mcg/mL of sulfur hexafluoride. 2.3 Reconstitution Instructions 12.2 Pharmacodynamics 2.4 Administration Instructions 12.3 Pharmacokinetics 4 CONTRAINDICATIONS 2.5 Imaging Guidelines 13 NONCLINICAL TOXICOLOGY Lumason is contraindicated in patients with: 3 DOSAGE FORMS AND STRENGTHS 13.1 Carcinogenesis, Mutagenesis, Impairment • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inac- 4 CONTRAINDICATIONS of Fertility tive ingredients in Lumason 5 WARNINGS AND PRECAUTIONS 14 CLINICAL STUDIES 5.1 Serious Cardiopulmonary Reactions 14.1 Echocardiography 5 WARNINGS AND PRECAUTIONS 5.2 Hypersensitivity Reactions 14.2 Ultrasonography of the Liver 5.1 Serious Cardiopulmonary Reactions 5.3 Systemic Embolization 14.3 Ultrasonography of the Urinary Tract Serious cardiopulmonary reactions, including fatalities have occurred uncommonly during or shortly following 5.4 Ventricular Arrhythmia Related to High 16 HOW SUPPLIED/STORAGE AND HANDLING administration of ultrasound contrast agents, including Lumason. These reactions typically occurred within 30 Mechanical Index 17 PATIENT COUNSELING INFORMATION minutes of administration. The risk for these reactions may be increased among patients with unstable cardio- 6 ADVERSE REACTIONS pulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable 6.1 Clinical Trials Experience *Sections or subsections omitted from the full congestive heart failure, or serious ventricular arrhythmias). Always have cardiopulmonary resuscitation person- 6.2 Postmarketing Experience prescribing information are not listed nel and equipment readily available prior to Lumason administration and monitor all patients for acute reactions. The reported reactions that may follow the administration of ultrasound contrast agents include: fatal cardiac or FULL PRESCRIBING INFORMATION respiratory arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supra- ventricular tachycardia, ventricular fibrillation, and ventricular tachycardia), hypertension, hypotension, dyspnea, WARNING: SERIOUS CARDIOPULMONARY REACTIONS hypoxia, chest pain, respiratory distress, stridor, wheezing, loss of consciousness, and convulsions. Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or follow- 5.2 Hypersensitivity Reactions [see Hypersensitivity reactions such as skin erythema, rash, urticaria, flushing, throat tightness, dyspnea, or anaphy- Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration lactic shock have uncommonly been observed following the injection of Lumason. These reactions may occur [see Warnings and Precautions (5.1)]. Assess all patients for the presence of any condition that precludes administration [see Contraindica- in patients with no history of prior exposure to sulfur hexafluoride lipid containing microspheres. Always have cardiopulmonary resuscitation personnel and equipment readily available prior to Lumason administration and tions (4)] . monitor all patients for hypersensitivity reactions. • Always have resuscitation equipment and trained personnel readily available [see Warnings and 5.3 Systemic Embolization Precautions (5.1)]. When administering Lumason to patients with cardiac shunt, microspheres can bypass filtering by the lung and enter the arterial circulation. Assess patients with shunts for embolic phenomena following Lumason adminis- 1 INDICATIONS AND USAGE tration. Lumason is only for intravenous and/or intravesical administration; do not administer Lumason by in- Echocardiography tra-arterial injection [see Dosage and Administration (2.1)]. Lumason is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular 5.4 Ventricular Arrhythmia Related to High Mechanical Index chamber and to improve the delineation of the left ventricular endocardial border. High ultrasound mechanical index values may cause microsphere cavitation or rupture and lead to ventricular Ultrasonography of the Liver arrhythmias. Additionally, end-systolic triggering with high mechanical indices has been reported to cause ven- Lumason is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal tricular arrhythmias. liver lesions. Lumason is not recommended for use at mechanical indices greater than 0.8. Ultrasonography of the Urinary Tract Lumason is indicated for use in ultrasonography of the urinary tract in pediatric patients for the evaluation of 6 ADVERSE REACTIONS suspected or known vesicoureteral reflux. The following serious adverse reactions are discussed elsewhere in the labeling: 2 DOSAGE AND ADMINISTRATION • Cardiopulmonary reactions [see Warnings and Precautions (5.1)] • Hypersensitivity reactions [see Warnings and Precautions (5.2)] 2.1 Important Administration Instructions 6.1 Clinical Trials Experience Do not administer Lumason by intra-arterial injection [see Warnings and Precautions (5.3)]. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the 2.2 Recommended Dosage clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not Echocardiography reflect the rates observed in practice. The recommended dose of Lumason after reconstitution is 2 mL administered as an intravenous bolus injection In completed clinical trials, a total of 6984 adult subjects (128 healthy volunteers and 6856 patients) received during echocardiography. During a single examination, a second injection of 2 mL may be administered to pro- long contrast enhancement. Follow each Lumason injection with an intravenous flush using 5 mL of 0.9% So- as single or multiple injections; however, some subjects received infusion dosing. The majority (75%) of subjects Lumason at cumulative doses ranging from 0.2 to 161 mL (mean 9.8 mL). Lumason was administered mainly dium Chloride Injection. received Lumason at cumulative doses of 10 mL or less. There were 64% men and 36% women, with an aver- Ultrasonography of the Liver age age of 59 years (range 17 to 99 years). A total of 79% subjects were Caucasian; 4% were Black; 16% were Adults Asian; <1% were Hispanic; and <1% were in other racial groups or race was not reported. The recommended dose of Lumason after reconstitution in adult patients is 2.4 mL administered as an intrave- nous injection during ultrasonography of the liver. During a single examination, a second injection of 2.4 mL may In the clinical trials, serious adverse reactions were observed in 2 subjects; one who experienced a hypersensi- tivity-type rash and presyncope and another who experienced anaphylactic shock shortly following Lumason be administered, if needed. Follow Lumason injection with an intravenous flush using 5 mL of 0.9% Sodium Chloride Injection. administration. The most commonly reported adverse reactions among patients (occurring among at least 0.2% of patients) are Pediatric Patients listed below (Table 1). Most adverse reactions were mild to moderate in intensity and resolved spontaneously. The recommended dose of Lumason after reconstitution in pediatric patients is 0.03 mL per kg administered an intravenous injection during ultrasonography of the liver. During a single examination, a second injection of Table 1. Adverse Reactions in Patients* 0.03 mL per kg may be administered, if needed. Do not exceed 2.4 mL per injection. Follow Lumason injection n = 6856 with an intravenous flush of 0.9% Sodium Chloride Injection. Number (%) of Patients with Adverse Reactions 340 (5%) Ultrasonography of the Urinary Tract Pediatric Patients Headache The recommended dose of Lumason after reconstitution is 1 mL. The bladder may be refilled with normal saline 65 (1%) Nausea 37 (0.5%) for a second cycle of voiding and imaging, without the need of a second Lumason administration. Dysgeusia 2.3 Reconstitution Instructions 29 (0.4%) Contents of Lumason Kit Injection site pain 23 (0.3%) Feeling Hot 18 (0.3%) Chest discomfort 17 (0.2%) Chest pain 12 (0.2%) Dizziness 11 (0.2%) Injection Site Warmth Glass vial 11 (0.2%) Mini-Spike (Lumason) and its plunger rod *occurring in at least 0.2% of patients • Inspect the Lumason kit and its components for signs of damage. Do not use the kit if the protective 6.2 Postmarketing Experience caps on the Lumason vial and prefilled syringe with 5 mL Sodium Chloride 0.9% Injection are not intact In the international postmarketing clinical experience and clinical trials, serious adverse reactions have uncom- or if the kit shows other signs of damage. monly been reported following administration of Lumason. Because these reactions are reported voluntarily • Under aseptic conditions, reconstitute Lumason by injecting the prefilled syringe with 5 mL Sodium from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a Chloride 0.9% Injection into the Lumason vial using the following illustrated steps: causal relationship to drug exposure. The serious adverse reactions include fatalities, especially in a pattern of 1. Connect the plunger rod to the prefilled syringe barrel symptoms suggestive of anaphylactoid/hypersensitivity reactions. Other serious reactions included arrhyth- by screwing it clockwise into the syringe (see Figure 1). mias and hypertensive episodes. These reactions typically occurred within 30 minutes of Lumason adminis- 2. Open the Mini-Spike blister and remove the syringe tip tration. cap (see Figure 2). 3. Open the Mini-Spike green cap and connect the sy- 8 USE IN SPECIFIC POPULATIONS ringe to the Mini-Spike by screwing it in clockwise (see 1 2 3 8.1 Pregnancy Figure 3). Risk Summary 4. Remove the flip cap plastic protective cap from the vial, remove the Mini-Spike There are no data with Lumason use in pregnant women to inform any drug-associated risks. No adverse de- spike protection and position the spike in the center of the rubber stopper of velopmental outcomes were observed in animal reproduction studies with administration of sulfur hexafluoride the vial. Press firmly inward until the spike is fully inserted in the stopper (see lipid-type A microspheres in pregnant rats and rabbits during organogenesis at doses up to at least 10 and 20 Figure 4). times, respectively, the maximum human dose of 4.8 mL based on body surface area (see Data). 5. Empty the content of the syringe into the vial by pushing on the plunger rod (see In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinical- 4 5 ly recognized pregnancies is 2-4% and 15-20%, respectively. 72 Data 14 CLINICAL STUDIES Animal Data 14.1 Echocardiography Lumason was administered intravenously to rats at doses of 0.2, 1, and 5 mL/kg (approximately 0.4, 2, and 10 A total of 191 patients with suspected cardiac disease and suboptimal non-contrast echocardiography received times the recommended maximum human dose of 4.8 mL, respectively, based on body surface area); Lumason Lumason in three multi-center controlled clinical trials (76 patients in Study A, 62 patients in Study B, and 53 doses were administered daily for about 30 consecutive days, from two weeks before pairing until the end of patients in Study C). Among these patients, there were 127 men and 64 women. The mean age was 59 years organogenesis. Lumason was administered intravenously to rabbits at doses of 0.2, 1, and 5 mL/kg (approxi- (range 22 to 96 years). The racial and ethnic representations were 79% Caucasian, 16% Black, 4% Hispanic, mately 0.8, 4, and 20 times the recommended maximum human dose, respectively, based on body surface area); Lumason doses were administered daily from gestation day 6 to day 19 inclusive. No significant findings - proximately 20% of the patients had a chronic pulmonary disorder and 30% had a history of heart failure. Of the on the fetus were observed. 106 patients for whom a New York Heart Association (NYHA) classification of heart failure was assigned, 49% 8.2 Lactation were Class I, 33% were Class II, and 18% were Class III. Patients with NYHA Class IV heart failure were not Risk Summary included in these studies. There are no data on the presence of Lumason in human milk, the effects on the breastfed infant, or the effects In Studies A and B, each patient received four intravenous bolus injections of Lumason (0.5, 1, 2, and 4 mL), in on milk production. The developmental and health benefits of breastfeeding should be considered along with randomized order. In Study C, each patient received two doses of Lumason (1 mL and 2 mL) in randomized the mother’s clinical need for Lumason and any potential adverse effects on the breastfed infant from Lumason order. All three studies assessed endocardial border delineation and left ventricular opacification. For each pa- or from the underlying maternal condition. tient in each study, echocardiography with Lumason was compared to non-contrast (baseline) echocardiogra- 8.4 Pediatric Use phy. A recording of 2D echocardiography was obtained from 30 seconds prior to each injection to at least 15 Ultrasonography of the Liver minutes after dosing or until the disappearance of the contrast effect, whichever was longer. Contrast and Effectiveness in pediatric patients has been established for use in ultrasonography of the liver for characteriza- non-contrast echocardiographic images for each patient were evaluated by two independent reviewers, who tion of focal liver lesions from adequate and well controlled trials in adult patients and a clinical study of 44 pe- were blinded to clinical information and the Lumason dose. Evaluation of left ventricular endocardial border diatric patients [see Clinical Studies (14)]. Safety of intravenous use of Lumason was based on evaluation of consisted of segment based assessment involving six endocardial segments and using two apical views (2- and published literature involving use of Lumason in over 900 pediatric patients. Non-fatal anaphylaxis was reported 4 chamber views). in one pediatric patient. Endocardial Border Delineation and Duration of Useful Contrast Effect Ultrasonography of the Urinary Tract In all three studies, administration of Lumason improved left ventricular endocardial border delineation. The Effectiveness in pediatric patients has been established for use in ultrasonography of the urinary tract for the majority of the patients who received a 2.0 mL dose of Lumason had improvement in endocardial border delin- evaluation of suspected or known vesicoureteral reflux from two published studies comprising a total of 411 eation manifested as visualization of at least two additional endocardial border segments. Table 3 demonstrates pediatric patients [see Clinical Studies (14)]. Safety of intravesical use of Lumason was based on evaluation of the improvement in endocardial border delineation following Lumason administration as a reduction in percent- published literature involving use of Lumason in over 6000 pediatric patients. No adverse reactions were re- age of patients with inadequate border delineation in at least one pair of adjacent segments (combined 2-cham- ported. ber and 4-chamber view). The results are shown by reader. Echocardiography Table 3. Reduction in Percentage of Patients with Inadequate Border Delineation Safety and effectiveness in pediatric patients have not been established for use in echocardiography. 8.5 Geriatric Use Study A Study B Of the total number of 6856 adult patients in clinical studies of Lumason, 39% were 65 and over, while 11% Study C Reader N = 76 N = 62 N = 53 were 75 and older. No overall differences in safety or effectiveness were observed between these subjects and Non-contrast Lumason Non-contrast Lumason Non-contrast younger subjects, and other reported clinical experience has not identified differences in responses between the Lumason A 60 (79%) 22 (33%) 31 (50%) 12 (19%) 12 (23%) 10 (19%) elderly or younger patients, but greater sensitivity of some older individuals cannot be ruled out. B 62 (82%) 29 (37%) 54 (87%) 6 (10%) 45 (85%) 20 (38%) 11 DESCRIPTION Following the first appearance of contrast within the left ventricle the mean duration of useful contrast effect Lumason (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous or intravesical ranged from 1.7 to 3.1 minutes. use is used to prepare the ultrasound contrast agent. The single-patient use kit contains the following three Left Ventricular Opacification items: In all three studies, complete left ventricular opacification was observed in 52% to 80% of the patients following